Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial

Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...

Why Is REPL Stock Gaining In Pre-Market Today?

Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy RP2.
Benzinga.com

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug

Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced ...

Replimune to face AdCom panel as lead drug accepted for FDA review

Replimune (REPL) stock dips as the FDA plans an advisory committee meeting after accepting the company's marketing ...

Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Roche Holding AG (OtherRHHVF)

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
EdSurge

Coding Platform Repl.it Raises $4.5M in Seed Round, Sees User Growth

REPL EFFECT: Repl.it, an online programming and computing platform, has raised $4.5 million in a seed round led by two general partners, Marc Andreessen and Andrew Chen, from the venture capital firm ...